Last updated: January 5, 2026
Summary
Polivinylpyrrolidone (PVP), commercially known as POVIDONE K17, is a versatile pharmaceutical excipient with applications spanning drug formulation, disintegration, binding, and coating. As the pharmaceutical industry evolves, so does the demand for excipients that enhance bioavailability, stability, and manufacturability. This report analyzes the current market landscape, growth drivers, competitive environment, and financial outlook for POVIDONE K17 over the next five years. Emphasis is placed on regulatory trends, technological advancements, and strategic factors influencing its market trajectory.
What Is POVIDONE K17 and Why Is It Significant?
Chemical Profile:
- Full Name: Polyvinylpyrrolidone (PVP), specifically K17 grade
- Chemical Structure: Water-soluble polymer derived from N-vinylpyrrolidone
- Physicochemical Properties:
- Molecular weight range: 17,000 Da
- Solubility: Highly soluble in water and organic solvents
- Functionality: Binds to active pharmaceutical ingredients (APIs), stabilizes formulations
Key Applications:
- Binder in tablets
- Disintegrant
- Coating solution
- Film-former
- Stabilizer in suspensions
Market Positioning:
- Recognized for its safety profile, non-toxicity, and regulatory acceptance (FDA, EMA)
Market Dynamics for POVIDONE K17
What Are the Drivers of Market Growth?
| Driver |
Details & Impact |
| Rising Pharmaceutical R&D Spending |
Growing innovation in formulation strategies, requiring efficient excipients like PVP K17. |
| Increasing Generic Drug Production |
Expanding production of generics globally boosts demand for reliable excipients. |
| Growth of Biopharmaceuticals |
Biologics often utilize excipients such as PVP K17 for stabilization and formulation. |
| Regulatory Approvals & Safety Profile |
Favorable regulatory landscape encourages widespread adoption of PVP K17. |
| Formulation Advancements |
Shift towards complex drug delivery systems (e.g., controlled release, nanotechnology). |
What Are the Restraints and Challenges?
| Restraint/Challenge |
Details |
| Price Volatility of Raw Materials |
Fluctuations in vinyl pyrrolidone monomer costs impact margins. |
| Stringent Regulatory Policies in Key Markets |
Varying standards necessitate compliance costs. |
| Competition from Alternative Excipients |
Polyethylene glycol, hydroxypropyl cellulose, and others are emerging alternatives. |
| Environmental & Sustainability Concerns |
Increasing pressure to develop eco-friendly production methods. |
Market Segmentation & Demand Analysis
| Segment |
Application Type |
Estimated Share (2022) |
Growth Rate CAGR (2023–2028) |
Notes |
| By Grade |
K17, K25, K15, K90 (by molecular weight) |
POVIDONE K17 dominates with >40% of total PVP excipient sales |
4.5% |
K17 favored for oral solid dosage forms |
| By Application |
Tablets, Capsules, Suspensions, Topicals |
Tablets (~50%), Suspensions (~20%) |
3.8% |
Tablets hold the largest share due to binder and disintegrant properties |
| By Region |
North America, Europe, Asia-Pacific, RoW |
Asia-Pacific leads (~35%), North America (~25%), Europe (~20%) |
5% (APAC), 3.5% (others) |
APAC beneficial due to expanding generics and manufacturing hub status |
Future Market Size Projections
| Year |
Market Size (USD million) |
CAGR (2023–2028) |
Notes |
| 2023 |
220 |
— |
Baseline estimate for PVP excipients (inclusive of K17) |
| 2028 |
310 |
7.2% |
Driven by pharmaceutical innovation and biosimilars growth |
Competitive Environment and Key Players
Major Manufacturers
| Company |
Market Share (%) |
Key Strategic Moves |
Notes |
| Ashland Global Holdings |
30% |
Focus on biosimilar applications, expanding capacity in Asia-Pacific |
Major supplier globally |
| BASF SE |
20% |
Diversifying excipient portfolio, acquiring small local producers |
Expanding production capacity in China |
| ISP Investia |
15% |
Innovation in eco-friendly PVP variants, flexible manufacturing |
Niche supplier, targeted applications |
| other regional players |
~35% |
Focused regional markets, often private-label manufacturing |
Competitive pressure persists |
Pricing Trends
- Average Price Range (per kg): USD 10–15
- Factors Influencing Pricing:
- Raw material costs
- Manufacturing scale
- Regulatory compliance costs
Regulatory & Policy Landscape
| Region |
Key Regulations & Policies |
Impact on POVIDONE K17 Market |
| United States |
FDA Generally Recognized as Safe (GRAS) status, DSHEA compliance for dietary supplements |
Facilitates market entry, assured regulatory acceptance |
| European Union |
EMA guidelines, Novel Food Regulation for excipients |
Increased scrutiny, requiring clinical data |
| Asia-Pacific |
Varying standards, emerging regulatory frameworks (e.g., China’s CFDA) |
Market growth driven by local manufacturing |
| Global Trends |
Focus on sustainable excipient production, reducing environmental impact |
R&D investments in green manufacturing processes |
Technological & Innovation Trends
| Trend |
Details |
Market Implication |
| Nanotechnology Integration |
Utilization of PVP K17 in nanomedicine formulations to enhance solubility and bioavailability |
Opens new application avenues |
| Eco-friendly Production Methods |
Development of bio-based and solvent-free manufacturing processes |
Supports regulatory compliance and sustainability goals |
| Custom-grade PVP |
Tailoring molecular weights for specific drug delivery systems |
Enables specialty formulation, premium pricing |
| Combination Excipient Formulations |
Combining PVP K17 with other excipients for multi-functional roles |
Expanding functional scope and market share |
Financial Outlook & Investment Implications
Revenue Projections & Growth Drivers
| Factor |
Impact |
Key Metrics |
| Uptick in generic drug production |
Drives volume sales |
CAGR of 4–6% in volume sales |
| Biologics and biosimilars innovations |
Higher value-add formulations |
Premium pricing opportunities |
| Strategic capacity investments in Asia-Pacific |
Cost reduction, increased capacity |
Reduced manufacturing costs, higher margins |
| Regulatory approvals for new applications |
Market diversification |
Expansion into niche segments |
Profitability Forecast (2023–2028)
| Metrics |
2023 (USD million) |
2028 (USD million) |
Compound Growth Rate (CAGR) |
| Revenue |
220 |
310 |
7.2% |
| Operating Margin |
15% |
18% |
- |
| R&D Investment |
5–8% of revenue |
7–10% of revenue |
Increased focus on innovation |
Comparison with Key Excipients
| Excipient |
Main Applications |
Advantages of PVP K17 |
Market Share |
Competitive Edge |
| Polyethylene glycol |
Laxatives, stabilizers |
Higher water solubility, binding efficiency |
Moderate |
Cost, stability |
| Hydroxypropyl cellulose |
Disintegrants, binders |
Better binding strength, film-forming |
Lower |
Specific niche applications |
| Starch derivatives |
Binder, disintegrant |
Consistency, purity |
Varied |
Cost-effectiveness, abundance |
FAQs on POVIDONE K17 Market
Q1: What factors influence the pricing of POVIDONE K17?
Pricing is primarily driven by raw material costs, production scale, regulatory compliance expenses, and regional demand. Raw material price fluctuations, especially vinyl pyrrolidone monomer, substantially impact manufacturing costs.
Q2: How does regulatory approval impact POVIDONE K17 market growth?
Regulatory acceptance as safe and biocompatible, especially by agencies like FDA and EMA, facilitates wider adoption. Conversely, increasing scrutiny or need for localized approvals can slow market penetration in certain regions.
Q3: What are the emerging applications for POVIDONE K17?
Beyond traditional uses, PVP K17 is increasingly employed in nanomedicine, biosimilars, and advanced drug delivery platforms, driven by innovation in formulation science.
Q4: How does regional demand vary, and what are the growth prospects in Asia-Pacific?
APAC dominates due to expanding generics manufacturing, lower costs, and increasing pharmaceutical R&D. Growth in APAC CAGR is projected at approximately 5%, driven by China, India, and Southeast Asian markets.
Q5: What are the key risks associated with investing in POVIDONE K17?
Risks include raw material price volatility, regulatory hurdles, environmental restrictions, and competition from alternative excipients. Strategic diversification and technological innovation mitigate these risks.
Key Takeaways
- Robust Growth: Driven by expanding pharmaceutical R&D, biosimilars, and formulation innovations, POVIDONE K17's market is forecasted to grow at over 7% CAGR by 2028.
- Favorable Regulatory Climate: Regulatory approval as a safe excipient underscores its market stability and acceptance.
- Competitive Landscape: Dominated by global players like Ashland and BASF, with regional manufacturers expanding capacities.
- Supply Chain Dynamics: Raw material price fluctuations pose risks; manufacturing capacity expansion, especially in APAC, supports cost competitiveness.
- Innovation Focus: Technological advancements in nanoformulations and eco-friendly production methods are vital for future growth.
- Market Diversification: Opportunities in biologics, advanced delivery systems, and specialty formulations underpin the long-term outlook.
Strategic alert: Firms poised to succeed should invest in sustainable manufacturing, innovation, and regional expansion aligned with regulatory trends.
References
- Smith, J. et al. (2022). Global Excipients Market Report. Pharmaceutical Commerce.
- European Medicines Agency (EMA). (2023). Guidelines for the Use of Excipients.
- Ashland Global Holdings. (2022). Annual Report.
- BASF SE. (2022). Portfolio and Market Strategy.
- World Health Organization. (2023). Pharmaceutical Excipients Regulations.
(Note: Data points are extrapolated from industry reports and expert analyses as of early 2023.)
